In addition, using a whole genome sequencing approach, Klampfl et al. and Nagalia et al identified calreticulin (CALR) mutations in the majority of ET and PMF patients that are negative for JAK2 or MPL alterations [3,4]. Here, JAK2 is linked to essential thrombocythemia.